New concepts in tissue specificity for prostate cancer and benign prostatic hyperplasia

Urology

Volumn 53, Issue 3 SUPPL. A, 1999, Pages 29-40

  De Marzo, Angelo M ^a   Coffey, Donald S ^a   Nelson, William G ^a  

^a JOHNS HOPKINS UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUTATHIONE TRANSFERASE; PROSTATE SPECIFIC ANTIGEN; PROTEIN P27;

ARTICLE; CARCINOGENESIS; CELL COMPARTMENTALIZATION; CELL NUCLEUS MATRIX; CHRONIC INFLAMMATION; CYTOSKELETON; DNA DAMAGE; HUMAN; LIPID DIET; MALE; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROSTATE CANCER; PROSTATE EPITHELIUM; PROSTATE HYPERTROPHY; SPECIES DIFFERENCE; STEM CELL; TISSUE SPECIFICITY;

EID: 0033059161     PISSN: 00904295     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0090-4295(98)00536-6     Document Type: Article

References (122)

1. De Marzo A., Meeker A., Epstein J., Coffey D. Prostate stem cell compartments expression of p27Kip1 in normal, hyperplastic and cancer cells . Am J Pathol. 153:1998;911-919.
2. De Marzo A.M., Nelson W.G., Meeker A.M., et al. Stem cell features of benign and malignant prostate epithelial cells. J Urol. 160:1998;2381-2392.
3. Partin A.W., Coffey D.S. The molecular biology, endocrinology, and physiology of the prostate and seminal vesicles. Walsh P.C., Retik A.B., Vaughan E.D., et al. Campbell's Urology. 7th edn. 1998;1381-1415 WB Saunders, New York.
4. Berry S.J., Isaacs J.T. Comparative aspects of prostatic growth and androgen metabolism with aging in the dog versus the rat. Endocrinology. 114:1984;511-520.
5. Berry S.J., Strandberg J.D., Saunders W.J., et al. Development of canine benign prostatic hyperplasia with age. Prostate. 9:1986;363-373.
6. Waters D.J., Patronek G.J., Bostwick D.G., et al. Comparing the age at prostate cancer diagnosis in humans and dogs (letter). J Natl Cancer Inst. 88:1996;1686-1687.
7. Waters D.J., Bostwick D.G. The canine prostate is a spontaneous model of intraepithelial neoplasia and prostate cancer progression. Anticancer Res. 17:1997;1467-1470.
8. Breslow N., Chan C.W., Dhom G., et al. Latent carcinoma of prostate at autopsy in seven areas. Int J Cancer. 20:1977;680-688.
9. Carter B.S., Carter H.B., Isaacs J.T. Epidemiologic evidence regarding predisposing factors to prostate cancer. Prostate. 16:1990;187-197.
10. Coffey D.S. Prostate cancer An overview of an increasing dilemma . Cancer. 71:1993;880-886.
11. Hanley AJ, Choi BC, and Holoway EJ: Cancer mortality among Chinese migrants: a review. Int J Epidemiol 24: 255-265, 1995.
12. Ormsby A.H., Haskell R., Ruthven S.E., et al. Bilateral primary seminal vesicle carcinoma. Pathology. 28:1996;196-200.
13. Bostwick D.G. Seminal vesicles. Bostwick D.G., Eble J.N. Urologic Surgical Pathology. 1997;423-456 Mosby, St. Louis.
14. Bostwick D.G. Spermatic cord and testicular adnexa. Bostwick D.G., Eble J.N. Urologic Surgical Pathology. 1997;647-674 Mosby, St. Louis.
15. Jones S, Martin RD, and Pilbeam DR (Eds). The Cambridge Encyclopedia of Human Evolution. Cambridge and New York, Cambridge University Press, 1992, pp 506.
16. Djuric Z., Heilbrun L.K., Reading B.A., et al. Effects of a low-fat diet on levels of oxidative damage of DNA of human peripheral nucleated blood cells. J Natl Cancer Inst. 83:1991;766-769.
17. Lemberger T., Desvergne B., Wahli W. Peroxisome proliferator-activated receptors a nuclear receptor signaling pathway in lipid physiology . Annu Rev Cell Dev Biol. 12:1996;335-363.
18. Isaacs J.T., Coffey D.S. Etiology and disease process of benign prostatic hyperplasia. Prostate. 2:(suppl):1989;33-50.
19. McNeal J.E. Normal anatomy of the prostate and changes in benign prostatic hypertrophy and carcinoma. Semin Ultrasound, CT MRI. 9:1988;329-334.
20. Qian J., Bostwick D.G. The extent and zonal location of prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia relationship with carcinoma in radical prostatectomy specimens . Pathol Res Pract. 191:1995;860-867.
21. Bostwick D.G. Prospective origins of prostate carcinoma. Prostatic intraepithelial neoplasia and atypical adenomatous hyperplasia. Cancer. 78:1996;330-336.
22. Cunha G.R. Role of mesenchymal-epithelial interactions in normal and abnormal development of the mammary gland and prostate. Cancer. 74:1994;1030-1044.
23. Fuchs E., Tyner A.L., Giudice G.J., et al. The human keratin genes and their differential expression. Curr Top Dev Biol. 22:1987;5-34.
24. Fuchs E. Keratins as biochemical markers of epithelial differentiation. Trends Genet. 4:1988;277-281.
25. Albers K., Fuchs E. The molecular biology of intermediate filament proteins. Int Rev Cytol. 134:1992;243-279.
26. Brawer M.K., Peehl D.M., Stamey T.A., Bostwick D.G. Keratin immunoreactivity in the benign and neoplastic human prostate. Cancer Res. 45:1985;3663-3667.
27. Getzenberg R.H., Pienta K.J., Coffey D.S. The tissue matrix cell dynamics and hormone action . Endocr Rev. 11:1990;399-417.
28. Nelson W.G., Pienta K.J., Barrack E.R., et al. The role of the nuclear matrix in the organization and function of DNA. Annu Rev Biophys Biophys Chem. 15:1986;457-475.
29. Getzenberg R.H., Coffey D.S. Tissue specificity of the hormonal response in sex accessory tissues is associated with nuclear matrix protein patterns. Mol Endocrinol. 4:1990;1336-1342.
30. Barrack E.R., Coffey D.S. The specific binding of estrogens and androgens to the nuclear matrix of sex hormone responsive tissues. J Biol Chem. 255:1980;7265-7275.
31. Partin A.W., Getzenberg R.H., Carmichael M.J., et al. Nuclear matrix protein patterns in human benign prostatic hyperplasia and prostate cancer. Cancer Res. 53:1993;744-746.
32. Reid L.M. Stem cell-fed maturational lineages and gradients in signals - relevance to differentiation of epithelia. Mol Biol Rep. 23:1996;21-33.
33. Potten C.S. Stem Cells. 1997;Academic Press, London.
34. Miller SJ, Lavker RM, and Sun T-T: Keratinocyte stem cells of cornea, skin and hair follicles, in Potten CS (Ed). Stem Cells. London, Academic Press, 1997, pp 331-362.
35. Wei Z.G., Sun T.T., Lavker R.M. Rabbit conjunctival and corneal epithelial cells belong to two separate lineages. Invest Ophthalmol Vis Sci. 37:1996;523-533.
36. Wei Z.G., Lin T., Sun T.T., Lavker R.M. Clonal analysis of the in vivo differentiation potential of keratinocytes. Invest Ophthalmol Vis Sci. 38:1997;753-761.
37. van den Bos C., Mosca J.D., Winkles J., et al. Human mesenchymal stem cells respond to fibroblast growth factors. Hum Cell. 10:1997;45-50.
38. Pierce G.B. Teratocarcinoma model for a developmental concept of cancer . Curr Top Dev Biol. 2:1967;223-246.
39. Pierce G.B., Speers W.C. Tumors as caricatures of the process of tissue renewal prospects for therapy by directing differentiation . Cancer Res. 48:1988;1996-2004.
40. Sell S., Pierce G.B. Maturation arrest of stem cell differentiation is a common pathway for the cellular origin of teratocarcinomas and epithelial cancers. Lab Invest. 70:1994;6-22.
41. Buick R.N., Pollak M.N. Perspectives on clonogenic tumor cells, stem cells, and oncogenes. Cancer Res. 44:1984;4909-4918.
42. Gandarillas A., Watt F.M. c-Myc promotes differentiation of human epidermal stem cells. Genes Dev. 11:1997;2869-2882.
43. Potten C.S., Morris R.J. Epithelial stem cells in vivo. J Cell Sci. 10:(suppl):1988;45-62.
44. Potten C.S., Loeffler M. Stem cells attributes, cycles, spirals, pitfalls and uncertainties.Lessons for and from the crypt . Development. 110:1990;1001-1020.
45. Bonkhoff H., Stein U., Remberger K. Multidirectional differentiation in the normal, hyperplastic, and neoplastic human prostate simultaneous demonstration of cell-specific epithelial markers . Hum Pathol. 25:1994;42-46.
46. Kinbara H., Cunha G.R., Boutin E., et al. Evidence of stem cells in the adult prostatic epithelium based upon responsiveness to mesenchymal inductors. Prostate. 29:1996;107-116.
47. Bonkhoff H., Remberger K. Differentiation pathways and histogenetic aspects of normal and abnormal prostatic growth a stem cell model . Prostate. 28:1996;98-106.
48. Kyprianou N., Isaacs J.T. Activation of programmed cell death in the rat ventral prostate after castration. Endocrinology. 122:1988;552-562.
49. DeKlerk D.P., Coffey D.S. Quantitative determination of prostatic epithelial and stromal hyperplasia by a new technique Biomorphometrics . Invest Urol. 16:1978;240-245.
50. McNeal J.E. Regional morphology and pathology of the prostate. Am J Clin Pathol. 49:1968;347-357.
51. McNeal J.E. The zonal anatomy of the prostate. Prostate. 2:1981;35-49.
52. McNeal J.E. Normal histology of the prostate. Am J Surg Pathol. 12:1988;619-633.
53. Bonkhoff H., Stein U., Remberger K. The proliferative function of basal cells in the normal and hyperplastic human prostate. Prostate. 24:1994;114-118.
54. McNeal J.E., Haillot O., Yemoto C. Cell proliferation in dysplasia of the prostate analysis by PCNA immunostaining . Prostate. 27:1995;258-268.
55. Verhagen A.P., Aalders T.W., Ramaekers F.C., et al. Differential expression of keratins in the basal and luminal compartments of rat prostatic epithelium during degeneration and regeneration. Prostate. 13:1988;25-38.
56. Verhagen A.P., Ramaekers F.C., Aalders T.W., et al. Colocalization of basal and luminal cell-type cytokeratins in human prostate cancer. Cancer Res. 52:1992;6182-6187.
57. Reiter R.E., Gu Z., Watabe T., Thomas G., et al. Prostate stem cell antigen a cell surface marker overexpressed in prostate cancer . Proc Natl Acad Sci USA. 95:1998;1735-1740.
58. Leake R. The cell cycle and regulation of cancer cell growth. Ann NY Acad Sci. 784:1996;252-262.
59. MacLachlan T.K., Sang N., Giordano A. Cyclins, cyclin-dependent kinases and cdk inhibitors implications in cell cycle control and cancer . Crit Rev Eukaryot Gene Expr. 5:1995;127-156.
60. Kamb A. Cell-cycle regulators and cancer. Trends Genet. 11:1995;136-140.
61. Hartwell L.H., Kastan M.B. Cell cycle control and cancer. Science. 266:1994;1821-1828.
62. McNeal J.E., Bostwick D.G. Intraductal dysplasia a premalignant lesion of the prostate . Hum Pathol. 17:1986;64-71.
63. Bostwick D.G., Montironi R. Prostatic intraepithelial neoplasia and the origins of prostatic carcinoma. Pathol Res Pract. 191:1995;828-832.
64. Bostwick D.G., Pacelli A., Lopez-Beltran A. Molecular biology of prostatic intraepithelial neoplasia. Prostate. 29:1996;117-134.
65. Polyak K., Hamilton S.R., Vogelstein B., et al. Early alteration of cell cycle-regulated gene expression in colorectal neoplasia. Am J Pathol. 149:1996;381-387.
66. Roberts J.M., Koff A., Polyak K., et al. Cyclins, cdks, and cyclin kinase inhibitors. Cold Spring Harb Symp Quant Biol. 59:1994;31-38.
67. Yasui W., Kudo Y., Semba S., Yokozaki H., et al. Reduced expression of cyclin-dependent kinase inhibitor P27(Kip1) is associated with advanced stage and invasiveness of gastric carcinomas. Jpn J Cancer Res. 88:1997;625-629.
68. Mori M., Mimori K., Shiraishi T., et al. P27 expression and gastric carcinoma. Nat Med. 3:1997;593.
69. Steeg P.S., Abrams J.S. Cancer prognostics past, present and p27 [news; comment] . Nat Med. 3:1997;152-154.
70. Tan P., Cady B., Wanner M., et al. The cell cycle inhibitor p27 is an independent prognostic marker in small (T1a,b) invasive breast carcinomas. Cancer Res. 57:1997;1259-1263.
71. Catzavelos C., Bhattacharya N., Ung Y.C., et al. Decreased levels of the cell-cycle inhibitor p27Kip1 protein prognostic implications in primary breast cancer . Nat Med. 3:1997;227-230.
72. Loda M., Cukor B., Tam S.W., et al. Increased proteasome-dependent degradation of the cyclin-dependent kinase inhibitor p27 in aggressive colorectal carcinomas. Nat Med. 3:1997;231-234.
73. Guo Y.P., Sklar G.N., Borkowski A., et al. Loss of the cyclin-dependent kinase inhibitor P27(Kip1) protein in human prostate cancer correlates with tumor grade. Clin Cancer Res. 3:1997;2269-2274.
74. Yang R.M., Naitoh J., Murphy M., et al. Low p27 expression predicts poor disease-free survival in patients with prostate cancer. J Urol. 159:1998;941-945.
75. Tsihlias J., Kapusta L.R., DeBoer G., et al. Loss of cyclin-dependent kinase inhibitor p27Kip1 is a novel prognostic factor in localized human prostate adenocarcinoma. Cancer Res. 58:1998;542-548.
76. Cheville J.C., Lloyd R.V., Sebo T.J., et al. Expression of p27kip1 in prostatic adenocarcinoma. Mod Pathol. 11:1998;324-328.
77. Cordon-Cardo C., Koff A., Drobnjak M., et al. Distinct altered patterns of p27KIP1 gene expression in benign prostatic hyperplasia and prostatic carcinoma. J Natl Cancer Inst. 90:1998;1284-1291.
78. Cote R.J., Shi Y., Groshen S., et al. Association of p27Kip1 levels with recurrence and survival in patients with stage C prostate carcinoma. J Natl Cancer Inst. 90:1998;916-920.
79. Dong J.T., Isaacs W.B., Isaacs J.T. Molecular advances in prostate cancer. Curr Opin Oncol. 9:1997;101-107.
80. Bova G.S., Isaacs W.B. Review of allelic loss and gain in prostate cancer. World J Urol. 14:1996;338-346.
81. Isaacs W.B. Molecular genetics of prostate cancer. Cancer Surv. 25:1995;357-379.
82. Pickett C.B., Lu A.Y. Glutathione S-transferases gene structure, regulation, and biological function . Annu Rev Biochem. 58:1989;743-764.
83. Coles B., Ketterer B. The role of glutathione and glutathione transferases in chemical carcinogenesis. Crit Rev Biochem Mol Biol. 25:1990;47-70.
84. Rushmore T.H., Pickett C.B. Glutathione S-transferases, structure, regulation, and therapeutic implications. J Biol Chem. 268:1993;11475-11478.
85. Lee W.H., Morton R.A., Epstein J.I., et al. Cytidine methylation of regulatory sequences near the pi-class glutathione S-transferase gene accompanies human prostatic carcinogenesis. Proc Natl Acad Sci USA. 91:1994;11733-11737.
86. Canada A.T., Roberson K.M., Vessella R.L., et al. Glutathione and glutathione S-transferase in benign and malignant prostate cell lines and prostate tissues. Biochem Pharmacol. 51:1996;87-90.
87. Moskaluk C.A., Duray P.H., Cowan K.H., et al. Immunohistochemical expression of pi-class glutathione S-transferase is downregulated in adenocarcinoma of the prostate. Cancer. 79:1997;1595-1599.
88. Cookson M.S., Reuter V.E., Linkov I., et al. Glutathione S-transferase PI (GST-pi) class expression by immunohistochemistry in benign and malignant prostate tissue. J Urol. 157:1997;673-676.
89. Lee W.H., Isaacs W.B., Bova G.S., et al. CG island methylation changes near the GSTPI gene in prostatic carcinoma cells detected using the polymerase chain reaction a new prostate cancer biomarker . Cancer Epidemiol Biomarkers Prev. 6:1997;443-450.
90. Brooks J.D., Weinstein M., Lin X., et al. CG island methylation changes near the GSTPI gene in prostatic intraepithelial neoplasia (PIN). Cancer Epidemiol Biomarkers Prev. 7:1998;531-536.
91. Cheng L., Shan A., Cheville J.C., et al. Atypical adenomatous hyperplasia of the prostate a premalignant lesion? Cancer Res. 58:1998;389-391.
92. Villers AA, McNeal JE, Freiha FS, et al: Development of prostatic carcinoma. Morphometric and pathologic features of early stages. Acta Oncologica : 145-151: 1991.
93. McNeal J.E. Cancer volume and site of origin of adenocarcinoma in the prostate relationship to local and distant spread . Hum Pathol. 23:1992;258-266.
94. Meyer J.S., Sufrin G., Martin S.A. Proliferative activity of benign human prostate, prostatic adenocarcinoma and seminal vesicle evaluated by thymidine labeling. J Urol. 128:1982;1353-1356.
95. Claus S., Wrenger M., Senge T., et al. Immunohistochemical determination of age related proliferation rates in normal and benign hyperplastic human prostates. Urol Res. 21:1993;305-308.
96. Casolone R., Portentoso P., Granata P., et al. Chromosome changes in benign prostatic hyperplasia and their significance in the origin of prostatic carcinoma. Cancer Genet Cytogenet. 68:1993;126-130.
97. Aly M.S., Cin P.D., Van de Voorde W., et al. Chromosome abnormalities in benign prostatic hyperplasia. Genes Chromosomes Cancer. 9:1994;227-233.
98. Qian J., Bostwick D.G., Takahashi S., et al. Comparison of fluorescence in situ hybridization analysis of isolated nuclei and routine histological sections from paraffin-embedded prostatic adenocarcinoma specimens. Am J Pathol. 149:1996;1193-1199.
99. Konishi N., Hiasa Y., Matsuda H., et al. Genetic variations in human benign prostatic hyperplasia detected by restriction landmark genomic scanning. J Urol. 157:1997;1499-1503.
100. Bonkhoff H. Role of the basal cells in premalignant changes of the human prostate a stem cell concept for the development of prostate cancer . Eur Urol. 30:1996;201-205.
101. Byrne R.L., Horne C.H., Robinson M.C., et al. The expression of waf-1, p53 and bcl-2 in prostatic adenocarcinoma. Br J Urol. 79:1997;190-195.
102. Krajewska M., Krajewski S., Epstein J.I., et al. Immunohistochemical analysis of bcl-2, bax, bcl-X, and mcl-1 expression in prostate cancers. Am J Pathol. 148:1996;1567-1576.
103. McDonnell T.J., Troncoso P., Brisbay S.M., et al. Expression of the protooncogene bcl-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52:1992;6940-6944.
104. Sherwood E.R., Berg L.A., Mitchell N.J., et al. Differential cytokeratin expression in normal, hyperplastic and malignant epithelial cells from human prostate. J Urol. 143:1990;167-171.
105. Xue Y., Smedts F., Umbas R., et al. Changes in keratin expression during the development of benign prostatic hyperplasia. Eur Urol. 32:1997;332-338.
106. Fraga C.F., True L.D., Kirk D. Enhanced expression of the mesenchymal marker, vimentin, in hyperplastic versus normal human prostatic epithelium. J Urol. 159:1998;270-274.
107. Ames B.N., Gold L.S., Willett W.C. The causes and prevention of cancer. Proc Natl Acad Sci USA. 92:1995;5258-5265.
108. Ames B.N. Mutagenesis and carcinogenesis endogenous and exogenous factors . Environ Mol Mutagen. 14:1989;66-77.
109. Cerutti P., Shah G., Peskin A., et al. Oxidant carcinogenesis and antioxidant defense. Ann NY Acad Sci. 663:1992;158-166.
110. Cerutti P.A., Trump B.F. Inflammation and oxidative stress in carcinogenesis. Cancer Cells. 3:1991;1-7.
111. Rosin M.P., Anwar W.A., Ward A.J. Inflammation, chromosomal instability, and cancer the schistosomiasis model . Cancer Res. 54:1994;1929s-1933s.
112. Lewis J.G., Adams D.O. Inflammation, oxidative DNA damage, and carcinogenesis. Environ Health Perspect. 76:1987;19-27.
113. Wink D.A., Vodovotz Y., Laval J., et al. The multifaceted roles of nitric oxide in cancer. Carcinogenesis. 19:1998;711-721.
114. Smith C.J., Gardner W.A. Jr. Inflammation-proliferation possible relationships in the prostate . Prog Clin Biol Res. 239:1987;317-325.
115. Platz E.A. Prostatitis and prostate cancer. New Dev Prostate Cancer Treat. 3:1998;71-73.
116. Donovan DA, and Nicholas PK: Prostatitis: diagnosis and treatment in primary care. Nurse Pract 22: 144-146, 149-156, 1997.
117. Blumenfeld W., Tucci S., Narayan P. Incidental lymphocytic prostatitis. Selective involvement with nom-malignant glands. Am J Surg Pathol. 16:1992;975-981.
118. Smigel K. Vitamin E reduces prostate cancer rates in Finnish trial U.S. considers follow-up . J Natl Cancer Inst. 90:1998;416-417.
119. Sharma O.P., Adlercreutz H., Strandberg J.D., et al. Soy of dietary source plays a preventive role against the pathogenesis of prostatitis in rats. J Steroid Biochem Mol Biol. 43:1992;557-564.
120. Krieger J.N., Riley D.E., Roberts M.C., et al. Prokaryotic DNA sequences in patients with chronic idiopathic prostatitis. J Clin Microbiol. 34:1996;3120-3128.
121. Riley D.E., Berger R.E., Miner D.C., et al. Diverse and related 16S rRNA-encoding DNA sequences in prostate tissues of men with chronic prostatitis. J Clin Microbiol. 36:1998;1646-1652.
122. Farrow DC, Vaughan TL, Hansten PD, et al: Use of aspirin and other nonsteroidal anti-inflammatory drugs and risk of esophageal and gastric cancer. Cancer Epidemiol Biomarkers Prev 7: 97-102, 1998.